Status | Study |
Completed |
Study Name: Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors Condition: Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor Date: 2014-04-29 Interventions: Drug: AZD5312 AZD5312 is a generation 2.5 antisense oligonucleotide (ASO) which is designed with the pur |
Recruiting |
Study Name: Study of Hepatic Function in Patients With Spinal and Bulbar Muscular Atrophy Condition: Liver Motor Neuron Disease Date: 2014-04-25 |
Completed |
Study Name: Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy Condition: Spinal and Bulbar Muscular Atrophy Date: 2013-12-29 Interventions: Drug: BVS857 BVS857 i.v. and e |
Terminated |
Study Name: A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT) Condition: Metastatic Breastcancer Estrogen Receptor Positive Breast Cancer Date: 2013-11-21 Interventions: Drug: DHEA DHEA: Daily oral administration of DHEA(Dehydroepiandrosterone) at the dosage of 100 mg/die i |
Recruiting |
Study Name: Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) Condition: Metastatic Breast Cancer Date: 2013-11-08 Interventions: Drug: Orteronel Other Name: Tak-700 |
Completed |
Study Name: Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women Condition: Libido Receptors, Androgen Polymorphism, Genetic Date: 2013-10-30 |
Recruiting |
Study Name: Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies Condition: Advanced Epithelial Ovarian Recurrent Epithelial Ovarian F Date: 2013-10-25 Interventions: Drug: Enzalutamide All enrolled patients will be treated with enzalutamide 160mg by mouth QD. Study drug |
Recruiting |
Study Name: Phase II Trial of Enzalutamide for CRPC With Correlative Assessment of Androgen Receptor Signaling Condition: Prostate Cancer Date: 2013-09-04 Interventions: Drug: Enzalutamide Administration: 160 mg orally once dail |
Terminated |
Study Name: GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer Condition: Estrogen Receptor Negative Breast Cancer Human Epidermal Growth Factor 2 Negative Carcinoma Date: 2013-07-25 Interventions: Drug: cisplatin |
Active, not recruiting |
Study Name: Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer Condition: Advanced, Androgen Receptor Positive Triple Negative Breast Cancer Date: 2013-06-26 Interventions: Drug: Enzalutamide 160 mg administered as four soft gelatin capsules orally once daily |